Application of two-dimensional gel-based mass spectrometry to functionally dissect resistance to targeted cancer therapy

Proteomics - Clinical Applications

Volumn 7, Issue 11-12, 2013, Pages 813-824

  Klein, Oliver ^a,b   Rohwer, Nadine ^a   de Molina, Katja Freitag ^c   Mergler, Stefan ^a   Wessendorf, Petra ^a   Herrmann, Marion ^a   Klose, Joachim ^a,b   Cramer, Thorsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

2DE; Gastric cancer; HIF 1 ; Targeted therapy; Therapy resistance

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PROTEOME;

ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER THERAPY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MASS SPECTROMETRY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CANCER; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WILD TYPE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MASS SPECTROMETRY; STOMACH NEOPLASMS;

EID: 84890020112     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300056     Document Type: Article

References (41)

1. Parkin, M., Global cancer statistics in the year 2000. LANCET Oncol. 2000, 33, 533-543.
2. Hohenberger, P., Gastric cancer. LANCET Oncol. 1991, 362, 305-315.
3. Rohwer, N., Lobitz, S., Daskalow, K., Jöns, T. et al., HIF-1alpha determines the metastatic potential of gastric cancer cells. Br. J. Cancer 2009, 100, 772-781.
4. Rohwer, N., Dame, C., Haugstetter, A., Wiedenmann, B. et al., Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PloS one 2010, 5, e12038.
5. Rohwer, N., Zasada, C., Kempa, S., Cramer, T., The growing complexity of HIF-1a 's role in tumorigenesis: DNA repair and beyond. Oncogene 2012, 32, 3569-3576.
6. Semenza, G. L., Hypoxia-inducible factor 1 (HIF-1) pathway. Science's STKE 2007, 2007, cm8.
7. Wenger, R. H., Cellular adaptation to hypoxia: O 2 -sensing protein hydroxylases, hypoxia-inducible transcription factors, and O 2 -regulated gene expression. FASEB J. 2002, 16, 1151-1162.
8. Wang, G. L., Jiang, B. H., Rue, E. a, Semenza, G. L., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
9. Ivan, M., Kondo, K., Yang, H. F., Kim, W. et al., HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O-2 sensing. Science 2001, 292, 464-468.
10. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I. et al., Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O-2-regulated prolyl hydroxylation. Science 2001, 292, 468-472.
11. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C. et al., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271-275.
12. Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A. et al., Ubiquitination of hypoxia-inducible factor requires direct binding to the β -domain of the von Hippel - Lindau protein. Nat. Cell Biol. 2000, 2, 423-427.
13. Vaupel, B. P., Mayer, A., Ho, M., Tumor hypoxia and malignant progression. Methods Enzymol. 2004, 381, 335-354.
14. Brown, L. M., Cowen, R. L., Debray, C., Eustace, A. et al., Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia. Mol. Pharmacol. 2006, 69, 411-418.
15. Sullivan, R. T., Paré, G. C., Frederiksen, L. J., Semenza, G. L., Graham, C. H., Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol. Cancer Therapeut. 2008, 7, 1961-1973.
16. Unruh, A., Ressel, A., Mohamed, H. G., Johnson, R. S. et al., The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003, 22, 3213-3220.
17. Hao, J., Song, X., Song, B., Liu, Y. et al., Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther. 2008, 15, 449-455.
18. Liu, L., Ning, X., Sun, L., Zhang, H. et al., Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008, 99, 121-128.
19. Nardinocchi, L., Puca, R., Sacchi, A., D'Orazi, G., Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol. Cancer 2009, 8, 1.
20. Sasabe, E., Zhou, X., Li, D., Oku, N. et al., The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int. J. Cancer 2007, 120, 268-277.
21. Fojo, T., Parkinson, D. R., Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? Clin. Cancer Res. 2010, 16, 5972-5980.
22. Gillies, R. J., Verduzco, D., Gatenby, R. A., Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 2012, 12, 487-493.
23. Bock, C., Lengauer, T., Managing drug resistance in cancer: lessons from HIV therapy. Nat. Rev. Cancer 2012, 12, 494-501.
24. Daskalow, K., Rohwer, N., Raskopf, E., Dupuy, E. et al., Role of hypoxia-inducible transcription factor 1α for progression and chemosensitivity of murine hepatocellular carcinoma. J. Mol. Med. 2010, 88, 817-827.
25. Schlüter, H., Apweiler, R., Holzhütter, H.-G., Jungblut, P. R., Finding one's way in proteomics: a protein species nomenclature. Chem. Central J. 2009, 3, 11.
26. Kasper, G., Mao, L., Geissler, S., Draycheva, A. et al., Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 2009, 27, 1288-1297.
27. Klose, J., Nock, C., Herrmann, M., Stühler, K. et al., Genetic analysis of the mouse brain proteome. Nat. Genet. 2002, 30, 385-393.
28. Wright, M. E., Han, D. K., Aebersold, R., Mass spectrometry-based expression profiling of clinical prostate cancer. Mol. Cell. Proteomics 2005, 4, 545-554.
29. Issaq, H. J., Fox, S. D., Chan, K. C., Veenstra, T. D., Global proteomics and metabolomics in cancer biomarker discovery. J. Separation Sci. 2011, 34, 3484-3492.
30. Rohwer, N., Welzel, M., Daskalow, K., Pfander, D. et al., Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res. 2008, 68, 10113-10120.
31. Claus Zabel, J. K., Protein extraction for 2DE. Methods Mol Biol. 2009, 519, 171-196.
32. Hartl, D., Rohe, M., Mao, L., Staufenbiel, M. et al., Impairment of adolescent hippocampal plasticity in a mouse model for Alzheimer's disease precedes disease phenotype. PloS One 2008, 3, e2759.
33. Grynkiewicz, G., Poenie, M., Tsien, R. Y., A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.
34. Mergler, S., Skrzypski, M., Sassek, M., Pietrzak, P. et al., Thermo-sensitive transient receptor potential vanilloid channel-1 regulates intracellular calcium and triggers chromogranin A secretion in pancreatic neuroendocrine BON-1 tumor cells. Cell. Signal. 2012, 24, 233-246.
35. Speit, G., Hartmann, A., The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. Meth. Mol. Biol. 2006, 113, 85-95.
36. Bauer, S., Grossmann, S., Vingron, M., Robinson, P. N., Ontologizer 2.0-a multifunctional tool for GO term enrichment analysis and data exploration. Bioinformatics 2008, 24, 1650-1651.
37. Semenza, G. L., Evaluation of HIF-1 inhibitors as anticancer agents. 2007, 12, 853-859.
38. Aziz, K., Nowsheen, S., Pantelias, G., Iliakis, G. et al., Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. Pharmacol. Therapeut. 2012, 133, 334-350.
39. Aley, P. K., Wilkinson, J. A, Bauer, C. C., Boyle, J. P. et al., Hypoxic remodelling of Ca(2+) signalling in proliferating human arterial smooth muscle. Mol. Cell. Biochem. 2008, 318, 101-108.
40. Stone, H. R., Morris, J. R., DNA damage emergency: cellular garbage disposal to the rescue? Oncogene 2013, doi: 10.1038/onc2013.60.
41. Tran, J. C., Zamdborg, L., Ahlf, D. R., Lee, J. E. et al., Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 2011, 480, 254-258.